EMEA-001529-PIP02-14-M03
Table of contents
Key facts
Active substance |
Testosterone
|
Therapeutic area |
Endocrinology-Gynaecology-Fertility-Metabolism
|
Decision number |
P/0508/2020
|
PIP number |
EMEA-001529-PIP02-14-M03
|
Pharmaceutical form(s) |
Nasal gel
|
Condition(s) / indication(s) |
Treatment of male hypogonadism
|
Route(s) of administration |
Nasal use
|
Contact for public enquiries |
Acerus Biopharma Inc.
Email: fholagh@aceruspharma.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|